Collegium Pharmaceutical, Inc. (COLL)
Oxford Ledge is still expanding full research coverage of COLL. A live quote, fundamentals, and analysis are available in the app; the SEC-sourced material below is what we currently have indexed here.
Business summary
Biopharmaceutical company commercializing ADHD and pain-management medications in the United States.
SEC filings
- 8-K Shareholder vote results 2026-05-15
- 8-K Completion of acquisition or disposition; Departure/election of directors or officers; Regulation FD disclosure; Financial statements and exhibits 2026-05-12
- 10-Q Quarterly financial report (unaudited) 2026-05-07
- 8-K Results of operations / financial condition; Regulation FD disclosure; Financial statements and exhibits 2026-05-07
- DEF 14A Proxy statement for shareholder vote 2026-04-07
Source: SEC EDGAR.
Insider activity
5 recent insider (SEC Form 4) filings on record for COLL. View the transactions in the terminal.
Source: SEC EDGAR (Form 4).
- Open COLL in the Oxford Ledge terminal — live quote, chart, and analysis in the app.
- Browse the covered-stock index
- Learn to analyze stocks yourself
The material above is drawn from public SEC EDGAR filings and is provided for educational purposes, not as investment advice. Live pricing and fundamentals are available in the terminal.